Substance / Medication

Danaparoid sodium

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

44 trials linked to this intervention

44
Total Trials
14
Recruiting
7
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Factor XI as a new target for prevention of thromboembolism in cardiovascular disease: a meta-analysis of randomized controlled trials.
Ali Ahmed E, Awad Mohamed K, Ali Karim et al. · J Thromb Thrombolysis · 2025
PMID: 38762711Meta-Analysis
Bioinformatics Analysis Reveals HIST1H2BH as a Novel Diagnostic Biomarker for Atrial Fibrillation-Related Cardiogenic Thromboembolic Stroke.
Jiang Wenbing, Jiang Lelin, Zhao Xiaoli et al. · Mol Biotechnol · 2025
PMID: 38825608Meta-Analysis
Left atrial appendage occlusion devices vs direct oral anticoagulants for atrial fibrillation: An updated systematic review and meta-analysis.
Fernandes Julia M, Pinheiro Rafael P S, Serpa Frans et al. · Curr Probl Cardiol · 2025
PMID: 39395644Meta-Analysis
Major clinical outcomes in symptomatic vs. asymptomatic atrial fibrillation: a meta-analysis.
Karakasis Paschalis, Pamporis Konstantinos, Siontis Konstantinos C et al. · Eur Heart J · 2025
PMID: 39428997Meta-Analysis
Perioperative direct oral anticoagulant management during cardiac implantable electronic device surgery: an updated systematic review and meta-analysis.
Ezenna Chidubem, Pereira Vinicius, Abozenah Mohammed et al. · J Interv Card Electrophysiol · 2025
PMID: 39546144Meta-Analysis
On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia.
Schenk Joachim F, Pindur Gerhard, Stephan Bernhard et al. · Clin Appl Thromb Hemost · 2003
PMID: 12643320Trial
Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients.
Polkinghorne Kevan R, McMahon Lawrence P, Becker Gavin J · Am J Kidney Dis · 2002
PMID: 12407644Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Danaparoid sodium (substance)
SNOMED CT
386954009
UMLS CUI
C0353453

Clinical Data

This intervention maps to 10 entities in the Ltrl knowledge graph.

4
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
44
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.